

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

Claim 1 (Currently amended) A tablet formulation ~~An oral pharmaceutical dosage form~~ comprising an acid susceptible proton pump inhibitor, ~~together with at least one or more~~ Non Steroidal Antiinflammatory Drugs (NSAID(s)), ~~Drug (NSAID)~~ and, optionally, pharmaceutically acceptable excipients, ~~characterized in that the dosage form is in the form of a fixed unit dosage form comprising at least two pharmaceutically active components,~~ and wherein at least the proton pump inhibitor is protected by an enteric coating layer.

Claim 2 (Canceled)

Claim 3 (Canceled)

Claim 4 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, further comprising ~~wherein the proton pump inhibitor is protected by two layers, an enteric coating layer and~~ a layer separating the enteric coating layer from the proton pump inhibitor.

Claim 5 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the tablet formulation ~~dosage form~~ comprises the ~~a~~ proton pump inhibitor and one NSAID.

Claim 6 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the proton pump inhibitor is omeprazole, an alkaline salt of omeprazole ~~thereof~~, a one ~~of its~~ single enantiomer of omeprazole or an alkaline salt of the single enantiomer ~~thereof~~.

Claim 7 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 6, wherein the proton pump inhibitor is S-omeprazole magnesium salt.

Claim 8 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the proton pump inhibitor is lansoprazole, a pharmaceutically acceptable salt of lansoprazole, a ~~or one of its~~ single enantiomer of lansoprazole enantiomers or a pharmaceutically acceptable salt of the single enantiomer thereof.

Claim 9 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the proton pump inhibitor is pantoprazole, a pharmaceutically acceptable salt of pantoprazole, a ~~or one of its~~ single enantiomer of pantoprazole enantiomers or a pharmaceutically acceptable salt of the single enantiomer thereof.

Claim 10 (Currently amended) The tablet formulation ~~A dosage form~~ according to any one of claims 6-9, wherein the NSAID(s) ~~NSAID~~ is selected from the group consisting of ibuprofen, diclofenac, piroxicam, ~~or~~ naproxen and ~~, or a~~ pharmaceutically acceptable salts ~~salt~~ thereof.

Claim 11 (Currently amended) The tablet formulation ~~A dosage form~~ according to any one of claims 6-9, wherein the NSAID is diclofenac or piroxicam, or a pharmaceutically acceptable salt thereof.

Claim 12 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the amount of the proton pump inhibitor is in the range of 10-80 mg and the amount of NSAID(s) is in the range of 10-800 mg.

Claim 13 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1, wherein the amount of the proton pump inhibitor is in the range of 10-40 mg and the amount of NSAID(s) is in the range of 10-500 mg.

Claim 14 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1 2, wherein the tablet formulation further comprises a first and second layer, and wherein the first layer comprises the ~~consists of two separate layers, one layer comprising a~~ proton pump inhibitor and the second ~~other~~ layer comprises the ~~comprising~~ one or more NSAID(s) NSAIDs.

Claims 15-21 (Canceled)

Claim 22 (Currently amended) The tablet formulation ~~A dosage form~~ according to claim 1 2, wherein the tablet formulation further comprises a first and second layer, and wherein the first layer comprises ~~consists of two separate layers, one layer comprising~~ the proton pump inhibitor in the form of enteric coating layered pellets and ~~compressed with~~ tablet excipients into a layer, and the second ~~other~~ layer comprises the ~~gives an extended release of~~ incorporated NSAID(s).

Claim 23 (Currently amended) The A tablet formulation ~~dosage form~~ according to claim 22, wherein the second layer further comprises ~~comprising the NSAID(s) is~~ a gelling matrix giving an extended release of the NSAID(s).

Claim 24 (Currently amended) The tablet formulation ~~A tableted dosage form~~ according to claim 1 2, wherein the tablet formulation comprises a core containing ~~is an enteric coating layered tablet comprising~~ a mixture of the proton pump inhibitor and the one or more NSAID(s), and wherein the tablet formulation is layered with the enteric coating layer and ~~NSAID comprising granules~~ optionally comprises ~~comprising~~ a water soluble or in water rapidly disintegrating separating layer in between the tablet core and the enteric coating layer.

Claim 25 (Currently amended) The tablet formulation ~~A-tableted dosage form~~ according to claim 1 ~~2~~, wherein the ~~tablet comprising enteric coating layered pellets of the~~ proton pump inhibitor is in the form of enteric coating layered pellets and the ~~compressed into a tablet,~~ ~~which~~ tablet formulation is covered by a ~~separate~~ layer comprising the NSAID(s).

Claim 26 (Currently amended) The tablet formulation ~~A-tableted dosage form~~ according to claim 25, wherein the layer comprising the NSAID(s) ~~tablet~~ is covered by a pigmented tablet filmcoating layer.

Claim 27 (Currently amended) The tablet formulation ~~A-tablet dosage form~~ according to claim 1 ~~2~~, wherein the proton pump inhibitor is in the form ~~tablet consists of two types~~ of enteric coating layered pellets, ~~one type comprises the proton pump inhibitor,~~ and the ~~other type comprises~~ NSAID(s) is in the form of enteric coating layered pellets ~~, together compressed with table excipients into a tablet.~~

Claim 28 (Currently amended) The tablet formulation ~~A-tablet dosage form~~ according to claim 1 ~~2~~, wherein the ~~tablet consists of enteric coating layered pellets comprising the~~ proton pump inhibitor is in the form of enteric coating layered pellets, and ~~pellets comprising~~ the NSAID(s) is in the form of pellets coating layered with an extended release film, ~~and these coatings layered pellets are compressed with tablet excipients into a tablet.~~

Claims 29-31 (canceled)

Claim 32 (Currently amended) A process for the manufacture of a tablet formulation ~~fixed dosage-form~~ comprising a proton pump inhibitor and one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), wherein the process comprises the steps: ~~in an enteric coating-layered-tablet characterized in that~~

(a) admixing the proton pump inhibitor ~~is admixed~~ with the NSAIDS(s) and pharmaceutically acceptable excipients;

(b) compressing ~~whereafter~~ the mixture ~~is compressed~~ into a tablet; , and

(c) covering the tablet ~~is covered~~ with an enteric coating layer and optionally covering the tablet covered with a separating layer before the enteric coating layer is applied.

Claim 33 (Currently amended) A method for the treatment of gastrointestinal side-effects associated with NSAID treatment in mammals and man by administering to a host in need thereof a therapeutically effective dose of the tablet formulation ~~a multiple-unit-tableted dosage form~~ according to any one of claims 1, 4-9, 12-14 or 22-28 ~~1 to 28~~.

Claim 34 (Currently amended) The ~~A~~ method according to claim 33, wherein the disorder is an upper gastrointestinal disorder associated with NSAID treatment.

Claim 35 (Canceled)

Claim 36 (Canceled)

Claim 37 (New) The tablet formulation according to any one of claims 6-9, wherein the NSAID is a NO-releasing NSAID, salt, hydrate, or ester thereof.

Claim 38 (New) The tablet formulation according to claim 37, wherein the NO-releasing NSAID is selected from the group consisting of NO-releasing diclofenac and NO-releasing naproxen.

Claim 39 (New) The tablet formulation according to any one of claims 6-9, wherein the NSAID is acetyl salicylic acid.

Claim 40 (New) The tablet formulation according to any one of claims 6-9, wherein the NSAID is a (COX)2 selective NSAID, salt, hydrate or ester thereof.

Claim 41 (New) The tablet formulation according to claim 22, wherein the second layer gives an extended release of the NSAID(s).

Claim 42 (New) The tablet formulation according to claim 41, wherein the second layer further comprises a gelling matrix giving an extended release of the NSAID(s).

Claim 43 (New) The tablet formulation according to any one of claims 22, 23, 25-28, 41 or 42 wherein the acid resistance of the enteric coating layered pellets comprising the proton pump inhibitor is in compliance with the requirements on enteric coating layered articles defined in the United States Pharmacopeia.

Claim 44 (New) The tablet formulation according to any one of claims 22, 23, 25-28, 41 or 42 wherein the acid resistance of the enteric coating layered pellets comprising the proton pump inhibitor does not decrease more than 10% in compliance with the requirements on enteric coating layered articles defined in the United States Pharmacopeia.

Claim 45 (New) The tablet formulation according to any one of claims 22, 23, 25-28, 41 or 42 wherein the enteric coating layer of the individual pellets comprises a plasticizer.